A US FDA advisory committee will weigh the persuasiveness of the efficacy data and the parameters of a restrictive Risk Evaluation and Mitigation Strategy (REMS) in considering whether Janssen R&D LLC’s esketamine should become the first drug approved for treatment-resistant depression in 10 years.
The Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet Feb. 12 to consider...





